Composition

1.Bifidobacterium longum subsp. longum BL21

2.Lacticaseibacillus rhamnosus LRa05

3.Bifidobacterium animalis subsp. lactis BLa80

4.Bifidobacterium breve BBr60

5.Lactobacillus acidophilus LA85

Main Function

Regulate blood sugar and improve glycolipid metabolism

Bifidobacterium longum subsp. longum BL21

Animal experiments show that BL21 can effectively reduce blood sugar levels in diabetic mice, improve

the antioxidant capacity of the livers, repair intestinal barrier damage, reduce inflammatory reactions,

and improve intestinal flora disorders in diabetic mice.

Lacticaseibacillus rhamnosus LRa05

It has the effects of lowering cholesterol, oral glucose tolerance, and relieving inflammation of the

digestive system. It has a synergistic effect in reducing blood lipids, blood sugar and body weight in

obese mice.

Bifidobacterium animalis subsp. lactis BLa80

It has good tolerance to gastric juice and bile salts, and also has proteolytic activity. It can metabolize

and produce angiotensin-converting enzyme inhibitory peptide to achieve anti-hypertensive effects.

Bifidobacterium breve BBr60

It can inhibit the growth of enteroinvasive Escherichia coli (EIEC), inhibit the adhesion and invasion of

EIEC to intestinal epithelial cells, and improve the intestinal flora.

Lactobacillus acidophilus LA85

It can effectively inhibits Staphylococcus aureus, Escherichia coli and Salmonella, significantly reduces

the adhesion of pathogens to HT 29 cells, regulates the abundance of intestinal flora such as Akkermansia,

and regulates the body's immunity by affecting cytokine levels.

Methods

• Subjects: 30 male C57BL/6J mice divided into 3 groups:
  
  

  • Control (CTL)
    
    

  • Diabetic model (T2DM)
    
    

  • Probiotic treatment (PRO)
    
    

• Induction of T2DM: High-fat diet (HFD) + streptozotocin (STZ)
  
  

• Treatment: Oral gavage of BL21 and LRa05 (1×10⁹ CFU each) for 11 weeks
  
  

• Assessment: Blood glucose, glucose tolerance, oxidative stress, inflammation markers, gut microbiota via 16S rRNA sequencing, histology of liver and intestines
  
  

• Conclusion

• The combined use of BL21 and LRa05 improves glucose metabolism, reduces inflammation and oxidative stress, and reshapes gut microbiota in diabetic mice—especially in the cecum, suggesting site-specific colonization. Their synergistic effects are promising for T2DM management, though clinical trials are needed.

Micro-Encapsulation Technology

Specification

Product : Blood Glucose Management Probiotic Premix Powder 

Specification : 100-600B CFU/G

Appearance : White to light yellow powder

Recommend dosage : 20-80 CFU/Day

Shelf life : 24 months

Application: Capsule / Tablet / Instant beverage